Williams JR, Carter CS, Insel T (1992)
Janney MS, Subramaniyan R, Dabas R, Lal S, Das NM, Godara SK
IGF-1 DESs short half-life makes it ideal for: Targeted injection into desired muscle groups Minimizing risk of systemic IGF-1 overexposure (which can lead to unwanted growth in non-target tissues) How It Differs From IGF-1 LR3 The DES(1-3) form of IGF-1 demonstrates higher potency for local anabolic effects due to enhanced receptor affinity and reduced binding to IGF binding proteins. Philippou et al., Cell Communication and Signaling Clinical & Performance Use Today While IGF-1 DES remains a research peptide and is not FDA-approved for human therapeutic use, it is widely used off-label by: Bodybuilders targeting lagging muscle groups (arms, calves, chest) Strength athletes recovering from tendon and ligament injuries Physique competitors preparing for contests Anti-aging practitioners promoting collagen synthesis and joint health It is also commonly stacked with: GH secretagogues (MK-677, CJC-1295, Ipamorelin) Recovery peptides (BPC-157 for Recovery, TB500) for comprehensive muscle growth + tissue repair protocols
Building better biomarkers: brain models in translational neuroimaging
Effect of GLY-GLY-HIS, GLY-HIS-LYS and their copper complexes on TNF--dependent IL-6 secretion in normal human dermal fibroblasts
